Fidelity Investments
AQST icon

Fidelity Investments’s Aquestive Therapeutics AQST Stock Holding History

Fidelity Investments’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.8K Sell
5,496
-9,413
-63% -$38.2K ﹤0.01% 4458
2025
Q4 		$96.3K Buy
14,909
+10,055
+207% +$62.7K ﹤0.01% 3763
2025
Q3 		$27.1K Buy
4,854
+2,524
+108% +$10.9K ﹤0.01% 4236
2025
Q2 		$7.71K Sell
2,330
-17
-0.7% -$49 ﹤0.01% 4602
2025
Q1 		$6.8K Sell
2,347
-73,298
-97% -$222K ﹤0.01% 4613
2024
Q4 		$269K Buy
75,645
+75,104
+13,882% +$346K ﹤0.01% 3156
2024
Q3 		$2.69K Buy
541
+511
+1,703% +$1.99K ﹤0.01% 4740
2024
Q2 		$77 Sell
30
-70
-70% -$234 ﹤0.01% 4994
2024
Q1 		$426 Buy
+100
New +$333 ﹤0.01% 4860
2023
Q3 		– Sell
-25
Closed -$41 – 5273
2023
Q2 		$41 Buy
+25
New +$45 ﹤0.01% 5049
2021
Q3 		– Sell
-1
Closed – – 4299
2021
Q2 		$0 Buy
+1
New +$4 ﹤0.01% 4204
2021
Q1 		– Sell
-400
Closed -$2K – 3954
2020
Q4 		$2K Buy
+400
New +$2.4K ﹤0.01% 3567

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments's AQST Position: Q1 2026 in Review

Fidelity Investments reduced its Aquestive Therapeutics (AQST) stake by 63% in Q1 2026, selling an estimated $38.2K and leaving 5,496 shares worth $22.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4458.

Fidelity Investments first reported a position in AQST in Q4 2020 and has held it in 12 quarters since. The position peaked at $269K in Q4 2024. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Fidelity Investments held 5,496 shares of Aquestive Therapeutics worth $22.8K as of Q1 2026.
  • Fidelity Investments sold 9,413 Aquestive Therapeutics shares in Q1 2026, an estimated $38.2K.
  • Aquestive Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4458 holding.
  • Fidelity Investments first reported a position in Aquestive Therapeutics in Q4 2020 and has held it in 12 quarters since.
  • Fidelity Investments's Aquestive Therapeutics position peaked at $269K in Q4 2024.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.